BioSpace News Archive

Abbott (NYSE: ABT) today announced late-breaking data on a number of its life-changing products to treat people with structural heart diseases.

Every year, approximately 10,000 people are rushed to the emergency department for fireworks injuries.

Canada has long been considered a top global jurisdiction for new medicine launches. However, a new report published by Life Sciences Ontario shows that new medicine launches in Canada fell dramatically in 2019.

Elixir Medical , a developer of innovative, drug-eluting cardiovascular devices, today announced outstanding 12-month data for the DynamX™ Coronary Bioadaptor System , the first coronary artery implant that adapts to vessel physiology. Results will be presented live tomorrow at 14:12 CEST on the Main Arena channel of the PCR e-Course as part of the Late Breaking Trials session by Stefan Verheye, MD, PhD, co-principal investigato

Minnesota medical device startup Cryosa completed its Series A-2 funding, raising $8.25 million to further develop its breakthrough therapies for obstructive sleep apnea (OSA). The round was led by life sciences firm, Santé Ventures, and HOYA Corporation (“HOYA”), with additional institutional and individual investors. This latest funding round will be used to engage in first-in-human clinical trials. The compa

Nurix Therapeutics, Inc., a company developing targeted protein modulation drugs, today announced the formation of a new adoptive cell therapy company, DeCART Therapeutics, which has been initially formed as a wholly owned subsidiary of Nurix.

If scientists understood how Alzheimer’s disease starts, they might have a better handle on how to stop it. That’s the premise behind a new $40.5 million collaborative research center in Seattle to build high-resolution maps of Alzheimer’s patients’ brains and identify how their neurons and other brain cells differ from those of healthy people.

Aldevron, a leading provider of products and services for the biotechnology industry, today announced an agreement with Ziopharm Oncology to produce plasmid DNA for T cell therapy of solid tumors.

joimax®, the German-based market leader in technologies and training methods for full-endoscopic and minimally invasive spinal surgery, is pleased to announce a new countrywide distributor in Taiwan, Hi-Clearance Inc.

The following resolutions were passed at Calliditas Therapeutics AB (publ) (“Calliditas”) annual general meeting held today, on June 25, 2020, in Stockholm.